Abstract
Objectives Enterococcus faecium is a common cause of hospital-acquired infections and is associated with vancomycin resistance. The hospital environment is often a reservoir for E. faecium due to its ability to survive on surfaces. In 2019 we noted increasing prevalence of vanA E. faecium causing bloodstream infections. We aimed to assess the hospital environment as a reservoir of vanA E. faecium.
Methods We conducted a point prevalence survey of the environment at the Alfred Hospital, Melbourne, Australia. We sampled all wards (n=12), 10 surface types and 357 surfaces. Resulting E. faecium isolates underwent short-read whole genome sequencing and were compared to invasive infection (bloodstream) isolates. The van operon, multi-locus sequence type (MLST) and core genome MLST (cgMLST) were determined.
Results Twenty percent (73/357) of surfaces isolated E. faecium with a median of 20% positivity per ward (IQR 11.6-30.6%). vanA and vanB were detected in 12/73 (16%) and 58/73 (79%) environmental genomes, respectively. In contrast, a higher proportion of bloodstream isolates carried vanA (32/72 [44%], P<0.001). Environmental genomes belonged to 10 MLSTs and 10 cgMLSTs, with ST796/ST78 accounting for 54/73 (74%) genomes. Clinical STs and cgMLSTs overlapped with environmental but were more diverse. We noted 13 putative genomic transmission clusters. One cluster contained 25/44 (57%) vanA genomes, with the majority being clinical (22/26 genomes, 85%). Environmental-clinical links were observed in 292/895 (33%) putative genomic transmission links. In completed assemblies, the vanA and vanB operons were located on pRE25-like plasmids and the chromosome, respectively.
Conclusion We noted a 20% prevalence of E. faecium environmental colonisation but the vanA operon was detected in only 12/73 genomes. We identified distinct environmental and patient reservoirs, with most environmental genomes carrying the vanB operon and having distinct STs/cgMLST clusters. Environment-clinical reservoir spillover was detected but accounted for a minority of putative transmission links.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Health and Medical Research Council of Australia (Emerging Leader 1 Fellowship APP1176324 to N.M., Practitioner Fellowship APP1117940 to A.Y.P.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was granted by the Alfred Hospital Ethics Committee (Project No. 81/24)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Accession numbers for all isolates have been included in the supplemental material.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
